Brain tumours are the leading cause of paediatric cancer-associated death worldwide. High-
grade glioma (HGG) represents a main cause of paediatric brain tumours and is associated …

Pediatric high-grade gliomas (pHGGs) are a group of tumors affecting approximately 0.85
children per 100,000 annually. The general outcome for these tumors is poor with 5-year …

Immune checkpoint inhibition (ICI) is effective for replication-repair-deficient, high-grade
gliomas (RRD-HGG). The clinical/biological impact of immune-directed approaches after …

Introduction Beyond focal radiation, there is no consensus standard therapy for pediatric
high-grade glioma (pHGG) and outcomes remain dismal. We describe the largest …

Background Many studies have demonstrated in the last years that once medulloblastoma
has recurred, the probability of regaining tumor control is poor despite salvage therapy …

Optimal management after recurrence or progression of high-grade gliomas is still
undefined and remains a challenge for neuro-oncology multidisciplinary teams. Improved …

Pediatric high-grade gliomas (pHGG) are a rare yet devastating malignancy of the central
nervous system's glial support cells, affecting children, adolescents, and young adults …

Purpose As there is no standard of care treatment for recurrent/progressing pediatric high-
grade gliomas (pHGG), we aimed to gain an overview of different treatment strategies …

Central nervous system (CNS) cancers account for approximately one quarter of all pediatric
tumors and are the leading cause of cancer-related death in children. More than 4,000 brain …

Background Diffuse midline glioma (DMG) is a devastating pediatric brain tumor
unresponsive to hundreds of clinical trials. Approximately 80% of DMGs harbor H3K27M …